Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
BioNexus Gene Lab Corp. (BGLC) had Return on Equity of -3.68% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$0.08M |
|
$-0.29M |
|
$0.06M |
|
$0.01M |
|
$0.36M |
|
$-0.28M |
|
$-0.00M |
|
$-0.29M |
|
$-0.29M |
|
$-0.29M |
|
$-0.29M |
|
$-0.29M |
|
$-0.29M |
|
$-0.26M |
|
$-0.22M |
|
2.42M |
|
2.42M |
|
$-0.12 |
|
$-0.12 |
|
| Balance Sheet Financials | |
$4.94M |
|
$1.54M |
|
$3.78M |
|
$8.73M |
|
$0.81M |
|
$0.05M |
|
$0.14M |
|
$0.95M |
|
$7.78M |
|
$7.78M |
|
$7.78M |
|
2.42M |
|
| Cash Flow Statement Financials | |
$-0.57M |
|
$0.40M |
|
$0.07M |
|
$2.49M |
|
$2.39M |
|
$-0.09M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.08 |
|
-- |
|
-- |
|
0.01 |
|
0.01 |
|
17.05% |
|
-370.81% |
|
-343.00% |
|
-- |
|
-376.14% |
|
-376.14% |
|
$-0.57M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
0.10 |
|
0.41 |
|
219.40 |
|
|
Return on Equity |
-3.68% |
-3.68% |
|
-3.28% |
|
-3.66% |
|
$3.22 |
|
$-0.24 |
|
$-0.24 |
|